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Abstract
Our recent studies have shown that the FoxM1B transcription factor is overexpressed in human
glioma tissues and that the level of its expression correlates directly with glioma grade. However,
whether FoxM1B plays a role in the early development of glioma, i.e., in transformation, is unknown.
In this study, we found that the FoxM1B molecule causes cellular transformation and tumor formation
in normal human astrocytes (NHAs) immortalized by p53 and pRB inhibition. Moreover, brain
tumors that arose from intracranial injection of FoxM1B-expressing immortalized NHAs displayed
glioblastoma multiforme (GBM) phenotypes, suggesting that FoxM1B overexpression in
immortalized NHAs not only transforms the cells but also leads to GBM formation. Mechanistically,
our results showed that overexpression of FoxM1B up-regulated NEDD4-1, an E3 ligase that
mediated the degradation and down-regulation of PTEN in multiple cell lines. Decreased PTEN in
turn resulted in the hyperactivation of Akt, which led to phosphorylation and cytoplasmic retention
of FoxO3a. Blocking Akt activation with PI3K/Akt inhibitors inhibited FoxM1B-induced
transformation of immortalized NHAs. Furthermore, overexpression of FoxM1B in immortalized
NHAs increased the expression of survivin, cyclin D1, and cyclin E, which are important molecules
for tumor growth. Collectively, these results indicated that overexpression of FoxM1B, in
cooperation with p53 and pRB inhibition in NHA cells, promoted astrocyte transformation and GBM
formation through multiple mechanisms.
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Introduction
Malignant glioma, including the most common subtype, astrocytoma, is aggressive, highly
invasive, and neurologically destructive. The prognosis for patients with malignant glioma is
poor (1,2). A number of pathways have been correlated with human gliomas, such as pRb, p53,
EGFR, PDGF/PDGFR, p16INK4a, p19ARF, telomerase, and Akt (3–6). Activation of the Akt
pathway is strongly implicated in glioma development and progression. In human studies, Akt
is activated in approximately 80% of GBMs (3). Activation of the Akt pathway in glioma is
often achieved by underexpression of its negative regulator phosphatase and tensin homolog
(PTEN). Studies have shown that PTEN is underexpressed in almost all GBM tumors,
compared with levels in normal brain tissue (7). Several mechanisms may be associated with
the underexpression of PTEN in gliomas, such as genetic alterations or promoter methylation
(8–11). However, gene deletion, mutation, LOH, or promoter methylation in the PTEN gene
is present in only about 50% of GBMs (7–11). Also, although PTEN genetic alterations are
rare in low-grade gliomas, these tumors exhibit lower PTEN protein levels than does normal
brain (7). Forthermore, underexpression of PTEN in the absence of genetic alterations or
promoter methylation is seen frequently in gliomas as well (8). Thus, mechanisms for PTEN
control at the transcriptional and posttranslational levels may be altered in glioma.
Ubiquitin-mediated degradation of PTEN has recently been reported, and NEDD4-1 (neural
precursor cell–expressed, developmentally down-regulated 4-1) has been identified as the E3
ligase for PTEN (12). NEDD4-1 negatively regulates PTEN stability by catalyzing PTEN
polyubiquitination. In fact, overexpression of NEDD4-1 has been shown to increase PTEN
polyubiquitination in a dose-dependent manner (12). Consistent with the tumor-suppressive
role of PTEN, NEDD4-1 was reported to be an oncogenic protein that regulates tumorigenesis
(12). Overexpression of NEDD4-1 increased cellular transformation by K-Ras. Elimination of
NEDD4-1 expression inhibited xenotransplanted tumor growth. Furthermore, NEDD4-1
regulates tumorigenesis by regulating Akt signaling via PTEN, and the oncogenic activity of
NEDD4-1 is PTEN-dependent (12). However, little is known about the regulation of
NEDD4-1.
FoxM1 is a member of the Forkhead box (Fox) transcription factor family known for its
function as a regulator of the cell cycle (13–17). Results from recent studies have revealed that
FoxM1 is substantially elevated in several aggressive human carcinomas and can contribute
to oncogenesis in many tissue types (18–25). For example, using transgenic and knockout
mouse models, studies have shown that FoxM1B plays essential roles in the developments of
hepatocellular carcinoma (20), prostate carcinomas (21), lung cancer (22,23) and colorectal
cancer in mice (24). Moreover, FoxM1 is an essential molecule in the regulation of oxidative
stress, which contributes to malignant transformation and tumor cell survival (16).
Increasing evidence indicates that FoxM1 may also contribute to oncogenesis in glioma. For
example, several studies found that aberrant expression of FoxM1 was a common molecular
alteration in malignant glioma (25–27). Another study that analyzed expression data from 201
GBM clinical specimens derived from TCGA showed the overexpression of FoxM1 in GBM
specimens compared with nontumor controls (28). In our own studies of the functional
importance of this factor, we found that FoxM1B was the predominant FoxM1 isoform in
human gliomas (25). FoxM1 levels in human glioma tissue directly correlated with glioma
grade and inversely correlate with the survival of GBM patients. In animal models, increased
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levels of FoxM1B expression in glioma cells enhanced the tumorigenicity, invasiveness, and
angiogenesis of these cells (25,29,30).
In this study, we sought to determine whether overexpression of FoxM1B induces the
transformation of human astrocytes into glioma cells, since FoxM1 expression is detected in
low-grade glioma. We used immortalized normal human astrocyte (NHA)-E6/E7/hTERT cells
because human astrocytes appear to be more genetically stable than do rodent cells (31), and
individual events believed to be important in gliomagenesis might be more readily studied in
the human cells (31–33). Moreover, the fact that NHA cells were not transformed by E6/E7/
hTERT suggests that inactivation of the p53 and pRb pathways was not sufficient to create
malignant astrocytes and that additional molecular events are needed (31). We found, to our
knowledge for the first time, that FoxM1B expression in NHA-E6/E7/hTERT cells resulted in
cellular transformation and GBM formation in nude mice, at least in part due to its role in the
regulation of NEDD4-1, the activation of Akt, and the induced expression of survivin, cyclin
D1, and cyclin E.
Materials and Methods
Cell lines and culture conditions
The NHA-E6/E7/hTERT cell line and Hs683 and HFU-251 glioma cell lines were described
previously (25,31,33). COS-1 cells were obtained from the American Type Culture Collection.
All of the cell lines were cultured in Dulbecco’s modified Eagle’s medium supplemented with
10% fetal bovine serum.
Retrovirus production and transduction
Retrovirus was produced with pLXSN-FoxM1B or pLXSN plasmids using the Phoenix A
retrovirus production system. NHA-E6/E7/hTERT cells were infected with the virus (10 MOI)
with 4 μg/mL Polybrene for 24 hours. To generate stable transduced cell lines, some infected
cells were cultured with neomycin for 2 weeks.
Northern blot analysis
Northern hybridization was performed by using a [32P]dCTP-radiolabeled FoxM1 cDNA
probe (25). Equal mRNA loading was monitored by hybridizing the same membrane with a
β-actin cDNA probe.
Western blot analysis
Standard Western blotting was performed with antibody against FoxM1, cyclin E, cyclin D1,
PTEN (Santa Cruz Biotechnology) or NEDD4-1, Akt, phospho-Akt, FoxO3a, phospho-
FoxO3a (Cell Signaling Technology), and survivin (Novus Biologicals).
Animals
Female athymic BALB/c nude mice were purchased from the National Cancer Institute
(Frederick, MD) and were maintained in institutional facilities approved by the Association
for Assessment and Accreditation of Laboratory Animal Care.
Colony formation in soft agar assay
Cells (5 × 103) were mixed with 0.3% agar solution in DMEM containing 10% fetal bovine
serum and 200 μg/ml of neomycin and poured this solution on top of a 0.60% agar layer in six-
well tissue culture plates. Plates were incubated at 37°C in a humidified atmosphere containing
5% CO2 for 21 days. Colonies were then stained with p-iodonitrotetrazolium violet (1 mg/ml)
and examined microscopically.
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Subcutaneous tumor growth
Cells (1 × 107) were injected subcutaneously into nude mice (25). The length (L), width (W),
and height (H) of the resulting tumors were measured once every 5 days. The volume of each
tumor was calculated by using the formula 1/2 × L × W × H at every time point.
Intracranial human glioma xenograft model
Cells (1 × 106) were injected intracranially into nude mice as described previously (25).
Animals showing general or local symptoms were killed; the remaining animals were killed
90 days after glioma-cell injection.
Histologic and immunohistochemical analysis of tumors
Tissue sections of brain tissue specimens were stained with H&E according to standard
protocols. Tissue sections were also used for immunostaining with antibodies against CD31
(BD Biosciences), glial fibrillary acidic protein (GFAP, Dako), phospho-Akt (Cell Signaling
Technology), PTEN, cyclin E, cyclin D1 (Santa Cruz Biotechnology), and survivin (Novus
Biologicals).
Cycloheximide chase experiments
5 × 105 cells were plated into 6-well plates. Twenty-four hours later, 50 mg/ml of
cycloheximide (CHX) was added to the cells, and the CHX treatment was terminated at the
indicated time points. Cell lysates were then prepared, and the expression of PTEN was
analyzed by Western blotting.
Chromatin immunoprecipitation assay
5 × 106 cells were prepared for the ChIP assay as according to the manufacturor’s instructions
with the ChIP assay kit (Cell signaling). Resulting DNA complexes were first
immunoprecipitated using indicated antibodies and then DNA was purified from the
complexes. The DNA was then subjected to PCR to amplify the putative FoxM1 binding region
1 (−642 to −828 bp) or region 2 (−841 to −993 bp) of the NEDD4-1 promoter using the primers
5′-TCTTCGTCACTGCCTTCTG-3′ and 5′-TTGGACTCGGGATCTGAAA -3′ or the primers
5′-TATGGATGCCTTATTTGGTG-3′ and 5′-TGAACTAGGACCTCCTGTAGAAT-3′,
respectively.
Statistical analyses
The significance of the in vitro results was determined by using Student’s t test (two-tailed),
whereas the significance of the in vivo data was determined by using the Mann-Whitney U
test.
Results
FoxM1 induces malignant transformation of immortalized NHAs
We infected NHA-E6/E7/hTERT cells with pLXSN-FoxM1B or control pLXSN retrovirus.
The infected cells were plated for growth in soft agar. Both NHA-E6/E7/hTERT cells and
NHA-E6/E7/hTERT cells infected with pLXSN were unable to grow in soft agar (Fig. 1A,
Table 1). However, colonies were obtained with NHA-E6/E7/hTERT cells infected with the
virus containing FoxM1B (Fig. 1A, Table 1). These results suggest that although inactivation
of the p53 and pRb pathways is not sufficient to convert normal astrocytes into malignant
glioma cells, such inactivation acts cooperatively with FoxM1B to achieve cellular
transformation.
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Immortalized NHAs that express FoxM1 are tumorigenic
Next, we created a series of cell lines immortalized by the expression of E6/E7/hTERT and
expressing FoxM1B. To avoid clonal selection and variation, we carried out three independent
infections of pLXSN-FoxM1B in NHA-E6/E7/hTERT cells and pooled G418-resistant
colonies to establish stable cell lines, designated as FoxM1B-transduced cell lines (NHA-E6/
E7/hTERT/FoxM1B-1, -2, and -3). FoxM1 protein expression was increased in FoxM1B-
transduced NHA-E6/E7/hTERT cell lines (Fig. 1B).
We then evaluated FoxM1-infected NHA-E6/E7/hTERT cells for their ability to form
subcutaneous tumors in nude mice; tumors formed within 3 weeks (Fig. 1C). No tumors
developed by 8 weeks in mice injected with parental NHA-E6/E7/hTERT or pLXSN–infected
cells. Thus, the results show that NHA-E6/E7/hTERT/FoxM1 cells are tumorigenic.
FoxM1 induces GBM formation of immortalized NHAs
We used an orthotopic xenograft model of human glioma to study the growth of these cells in
the brains of nude mice. Intracranially implanted NHA-E6/E7/hTERT or pLXSN–infected
cells did not form tumors by 90 days after injection (Table 1). In contrast, intracranially injected
FoxM1B-infected NHA-E6/E7/hTERT cells did form brain tumors in nude mice and
significantly shortened their survival duration (Table 1). We also examined the histologic
features of brain tumors that arose from NHA-E6/E7/hTERT/FoxM1 cells in the brains of nude
mice. The lesions were characterized by high cellularity and invasiveness, were pleomorphic,
and exhibited microvessel proliferation and necrosis (Fig. 1D), all distinct histologic features
of human GBM. In addition, the brain tumor cells were positive for GFAP, but the level of
expression was less than in the astrocytes in the surrounding tissue, indicating a human
astrocytic origin of the tumors (Fig. 1D). These findings suggest that the overexpression of
FoxM1B in immortalized NHAs cells lead to the formation of GBM in nude mice.
Increased FoxM1 expression leads to Akt activation
In animal studies, activation of Akt appears to be essential for the formation of GBMs from
genetically modified neural progenitors and normal human astrocytes (33,34). Thus, we
examined whether overexpression of FoxM1 affects the activation status of Akt in NHA-E6/
E7/hTERT cells. We found that pLXSN-FoxM1B infections induced more phosphorylation
and activation of Akt than did infection with retroviral pLXSN or Ras (Fig. 2A). In contrast,
overexpression of FoxM1 did not affect ERK-1/2 activation, a different pathway from Akt
(Fig. 2A). NHA-E6/E7/hTERT/FoxM1B brain tumors also expressed phosphorylated Akt (p-
Akt) (Fig. 2B). Furthermore, overexpression of FoxM1 in NHA-E6/E7/hTERT by transient
pLXSN-FoxM1B infection induced the nuclear translocation of Akt and the cytoplasmic
retention of FoxO3a protein (Fig. 2C), which have been reported as significant predictors of
p-Akt status in gliomas (35). These results indicate that increased FoxM1 expression leads to
Akt activation and subsequently inhibits FoxO3a function.
Blocking Akt activation inhibits FoxM1-induced transformation of immortalized NHAs
To determine whether FoxM1 induces transformation of immortalized NHAs through the Akt
pathway, we treated NHA-E6/E7/hTERT/FoxM1 cells with PI3K inhibitors LY294002 and
wortmannin. Both treatments inhibited the expression of p-Akt in the cells (Fig. 2D, left).
Furthermore, blockade of Akt activation by LY294002 and wortmannin suppressed the
transformation of immortalized NHAs, as determined by a colony-formation assay (Fig.
2D,right). Therefore, these data suggest that Akt activation is an important step in the FoxM1-
mediated transformation of immortalized NHAs into glioma cells.
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Increased FoxM1 expression leads to PTEN reduction and Akt activation
It is known that PTEN is an important molecule that regulates Akt activity by inhibiting PI3K
(36,37). To further define how FoxM1 activates the Akt pathway in NHA cells, we examined
PTEN expression in these cells. Levels of PTEN expression were substantially lower in NHA-
E6/E7/hTERT/FoxM1B cells than in NHA-E6/E7/hTERT or NHA-E6/E7/hTERT/pLXSN
control cells (Fig. 3A,left). The observed decrease in PTEN expression in these cells was
accompanied by enhanced Akt pathway signaling, as was evident by concomitant increases in
the level of p-Akt, but not in the level of total Akt (Fig. 3A,left). NHA-E6/E7/hTERT/FoxM1B
brain tumors also had lower levels of PTEN expression than did brain tissues from the mice
injected with NHA-E6/E7/hTERT/pLXSN cells (Fig. 3A, right). Moreover, knockdown of
FoxM1 in NHA-E6/E7/hTERT/FoxM1B cells restored PTEN expression and reversed the up-
regulation of p-Akt in the cells (Fig. 3B, left). Furthermore, the overexpression of FoxM1 in
Hs683 glioma cells down-regulated PTEN and up-regulated p-Akt expression (Fig. 3B,
right).
FoxM1 regulates PTEN expression on the posttranscriptional level
To study the mechanism that may be responsible for the down-regulation of PTEN by FoxM1,
we first examined the RNA levels of PTEN and found that the transcriptional levels of PTEN
were similar in both the NHA-E6/E7/hTERT/FoxM1 and NHA-E6/E7/hTERT/pLXSN control
cells (Fig. 3C). Next, we inhibited protein translation in cells with use of CHX treatment and
analyzed PTEN protein levels at the indicated times. As shown in Figure 3D (left and
middle), overexpression of FoxM1 in NHA-E6/E7/hTERT/FoxM1 cells resulted in an increase
in the endogenous PTEN degradation rate, compared with NHA-E6/E7/hTERT/pLXSN
control cells. Overexpression of FoxM1 in COS-1 cells also resulted in a decreased level of
exogenous PTEN protein (Fig. 3D, right). Such a decrease in PTEN protein level can be
blocked by proteasomal inhibitor MG132 (Fig. 3D, right). These results indicated that the
decreased PTEN expression in FoxM1 overexpression cells was due, at least in part, to the
increased stability of PTEN protein.
FoxM1 down-regulates PTEN expression by regulating NEDD4-1
To study how FoxM1 regulates PTEN degradation, we first performed protein-protein binding
experiments on FoxM1 and PTEN. We did not find direct binding of FoxM1 with PTEN (data
not shown), indicating that the regulation of PTEN by FoxM1 is probably an indirect
mechanism. On the other hand, NEDD4-1 has been identified as an E3 ligase that can promote
PTEN ubiquitination and degradation. We determined that endogenous NEDD4-1 can indeed
regulate PTEN in NHA-E6/E7/hTERT/FoxM1 by showing that the knockdown of NEDD4-1
by siRNA in the cells caused an increase in endogenous PTEN (Fig. 4A). Therefore, this result
confirmed the role of NEDD4-1 as PTEN E3 in ligase in the cells.
We next examined the level of NEDD4-1 in the NHA cells. As shown in Figure 4B, the protein
level of NEDD4-1 was up-regulated in NHA-E6/E7/hTERT/FoxM1B cells compared with
levels in NHA-E6/E7/hTERT and NHA-E6/E7/hTERT/pLXSN cells, whereas the protein
level of PTEN was down-regulated in the NHA-E6/E7/hTERT/FoxM1B cells. Moreover, the
mRNA level of NEDD4-1 was up-regulated in NHA-E6/E7/hTERT/FoxM1B cells (Fig. 4B,
middle). In contrast, knocking down FoxM1 from NHA-E6/E7/hTERT/FoxM1B cells
inhibited the expression of NEDD4-1, restored PTEN expression, and inhibited p-Akt in the
cells (Fig. 4B, right).
To determine whether NEDD4-1 could be a direct transcriptional target of FoxM1, we scanned
~2-kb promoter regions of NEDD4-1 gene with the FoxM1 DNA binding consensus sequence
(13), and two FoxM1 putative binding sites (−740 to −750 bp and −903 to −913bp) were found
in the promoter (Fig. 4C). To determine whether FoxM1 binds directly to the human
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NEDD4-1 promoter, we performed ChIP assays using two pairs of PCR primers to DNA
sequences (−642/−828 bp or −841/−993 bp) in the vicinity of these potential FoxM1 binding
sites. Indeed, ChIP assays in NHA-E6/E7/hTERT/pLXSN or FoxM1B cells with antibodies
specific to either FoxM1 or FoxO3a (control) showed that FoxM1 protein is directly bound to
the endogenous NEDD4-1 promoter compared to the FoxO3a control (Fig. 4C). Moreover, in
the NHA-E6/E7/hTERT/FoxM1B cells that expressed high FoxM1 levels, there is an increased
binding of FoxM1 protein to the promoter as compared to that in NHA-E6/E7/hTERT/pLXSN
(Fig. 4C). These findings demonstrate that FoxM1 bound specifically to FoxM1-binding sites
in the NEDD4-1 promoter in vivo, suggesting NEDD4-1 could be a direct transcriptional target
of FoxM1.
To examine whether FoxM1 regulated NEDD4-1 in other cells, Hs683 glioma cells were
transfected with FoxM1. Overexpression of FoxM1 in Hs683 glioma cells up-regulated
NEDD-4, decreased PTEN, and increased p-Akt expressions (Fig. 4D, left). Furthermore,
COS-1 cells were cotransfected with PTEN in the presence or absence of FoxM1
overexpression. Overexpression of FoxM1 in COS-1 also caused an increase in NEDD4-1 and
a decrease in exogenous PTEN protein (Fig. 4D, right). Taken together, the above data
indicated that FoxM1 regulated NEDD4-1 expression, hence PTEN expression, in the cells.
FoxM1 induces multiple occurrences of cancer-related gene expression
To further explore the molecular mechanisms involved in FoxM1-mediated GBM formation,
we measured the expression of cyclin D1, cyclin E, and survivin in FoxM1B–overexpressed
cell lines and in the brain tumor tissues of mice. Some of these molecules have been previously
reported to be the downstream targets of Akt and/or FoxM1 and to be important factors for
glioma proliferation (20,24,25,38,39). Our results showed that cyclin D1, cyclin E, and survivin
are also highly expressed in the FoxM1B–overexpressed cells and in the brain tumors that arose
from injection of NHA-E6/E7/hTERT/FoxM1B cells (Fig. 5A and 5B). In addition, knockdown
of FoxM1 expression down-regulated these genes significantly in HFU-251 GBM cells (Fig.
5C). These results indicated that the overexpression of FoxM1 in NHA cells not only inhibited
PTEN and activated the Akt pathway, but also induced the expression of multiple cell cycle–
related genes, which are important molecules for tumor growth.
Discussion
Although our previous studies had indicated that aberrant FoxM1B expression is critical to the
regulation of tumorigenicity, invasion, and angiogenesis of human glioma cells, it was not
known whether FoxM1B plays an important role in the transformation of human astrocytes
into glioma cells. In this study, we found that overexpression of FoxM1 in immortalized human
astrocytes not only transforms the cells but also causes them to progress into GBM cells in the
brain. We also provided evidence that FoxM1 up-regulated the expression of NEDD-4, which
resulted in increased PTEN protein degradation. Furthermore, the increased PTEN protein
degradation in turn led to the up-regulation of activation of Akt pathway, a potential mechanism
for the development of GBM.
Glioma formation and progression are widely regarded as multistep processes resulting from
complex interplay between multiple genetic and epigenetic events (3–6,31–33,40,41). Studies
have shown that the loss of p53 and pRb pathways is not sufficient to induce glioma and that
additional molecular events are needed such as Ras activation and PTEN loss (40,41). Our
results support this finding; specifically, we found that a combinationof FoxM1
overexpression, loss of p53 and pRb pathways, and human telomerase reverse transcriptase
overexpression is sufficient to induce NHA cells to transform into glioma.
Dai et al. Page 7
Cancer Res. Author manuscript; available in PMC 2011 April 1.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Moreover, our results support the involvement of PTEN underexpression in transformation
and in GBM formation. Brain-specific inactivation of PTEN in a mouse model caused increased
astrocyte proliferation that may render these cells susceptible to neoplastic transformation
(42,43). PTEN heterozygous knockout accelerated astrocytoma development in mice in which
the Rb family proteins were inactivated (44). Moreover, it has been shown that successive loss
of each PTEN allele may contribute to de novo formation of high-grade astrocytoma and
progression into glioblastoma, respectively (45).
Numerous studies have suggested that PTEN can be inactivated not only by gene deletion and
mutation but also by defects in posttranslational regulation during tumorigenesis (12,46–47).
Recent studies postulated that PTEN is subject to ubiquitination mediated by NEDD4-1, an
E3 ligase, leading to PTEN degradation (12,47). Moreover, the overexpression of NEDD4-1
was shown to induce PTEN degradation and promote K-Ras–mediated transformation (12). In
bladder cancers, the PTEN level was inversely correlated with the level of NEDD4-1 (12). In
breast cancer, NEDD4-1 was shown to be critical for targeting PTEN for degradation (47).
Therefore, these studies suggest that NEDD4-1 shows oncogenic activity that is PTEN-
dependent.
In the current study, we found that knockdown of NEDD4-1 in NHA-E6/E7/hTERT/FoxM1B
cells caused an increase in endogenous PTEN, suggesting the role of NEDD4-1 in PTEN
regulation in glioma cells. Furthermore, we demonstrated that the overexpression of FoxM1
down-regulated PTEN expression in NHA-E6/E7/hTERT, Hs683, and COS-1 cells (all with
wild-type PTEN). The mechanism for the overexpression of FoxM1 that accelerates PTEN
degradation is as follows: FoxM1 regulates the expression of NEDD4-1, which promotes
PTEN ubiquitination and degradation in these cells.
PTEN inactivation could result in uncontrolled PI3K/Akt signaling activation, a mechanism
of tumor formation. We have observed that increased expression of FoxM1 in NHA-E6/E7/
hTERT caused a significant increase in the level of p-Akt and induced tumor colony formation
in a soft agar assay and tumor formation in a mouse brain tumor model. Moreover, using the
PI3K-specific inhibitors LY294002 and wortmannin can inhibit FoxM1-induced colony
formation in vitro. Therefore, the results indicate that PI3K/Akt activation plays an important
role in the glioma formation.
Several studies have reported that cyclin D1 and cyclin E expression correlate significantly
with the degree of malignancy in astrocytomas (49). Survivin expression is also increased in
GBMs and correlates with patient survival (50). In this study, we found that FoxM1B
overexpression in glioma cells significantly increased survivin, cyclin D1, and cyclin E
expression, consistent with findings in other types of cells (5,11). Thus, the molecular
mechanisms by which FoxM1 regulates the growth of glioma cells are associated with
increasing the expression of these molecules that function as cell-cycle regulators and/or
inhibitors of tumor cell apoptosis and are critical for tumor cell proliferation.
In summary, our findings demonstrated that FoxM1 plays an important role in promoting
astrocyte transformation and GBM formation by the regulation of multiple factors. Of more
importance, we have provided a new mechanism of FoxM1-induced transformation and GBM
formation involving the overexpression of FoxM1 that up-regulates the expression of
NEDD4-1 and hence destabilizes PTEN and activates the Akt pathway. Our findings strongly
suggest that FoxM1 plays an important role in glioma transformation and may be a therapeutic
target for glioma.
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Figure 1. Effects of FoxM1B expression on transformation and glioma growth in vivo
A, Colony-formation assays were performed with the NHA-E6/E7/hTERT cells infected with
pLXSN-FoxM1B or pLXSN retrovirus, and without retroviruses (Mock), as indicated. Figure
shows the typical colony-formation assay result. B, Determination of overexpression of
FoxM1B in three independent pLXSN-FoxM1 retrovirus–transduced E6/E7/hTERT cell lines
by Northern (upper panel) and Western (lower panel) blot analyses. C, Cells (1 × 107 cells/
mouse) from NHA-E6/E7/hTERT, pLXSN, and three independent pLXSN-FoxM1B cell lines
were injected subcutaneously into nude mice (n = 5), and tumor formation was determined.
The results shown are for one representative experiment of two. D, Histological features of
NHA-E6/E7/hTERT-FoxM1B brain tumors. a, A highly invasive phenotype of the tumors
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(arrows indicate invasive cells; H&E stains, magnification ×100). b, Increased microvessel
proliferation in the tumors (CD34 stains, magnification ×100). c, Microscopic necrosis with
pseudopalisading (H&E staining, magnification ×100). d, Brain tumor cells are GFAP positive
(arrows indicate astrocytes in the surrounding tissue; GFAP stains, magnification ×200).
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Figure 2. Overexpression of FoxM1 increased p-Akt but not p-ERK-1/2
A, The expression of FoxM1, p-Akt, total Akt, FoxO3a, p-FoxO3a, ERK-1/2, and p-ERK-1/2
on NHA-E6/E7/hTERT/FoxM1B cells or parental and NHA-E6/E7/hTERT/pLXSN cells was
analyzed by using Western blotting. B, Paraffin sections from brain injected with pLXSN- and
pLXSN-FoxM1B-transduced NHA-E6/E7/hTERT cells (tumors) were stained with antibody
against p-Akt. C, Immunofluorescent microscopic analyses of Akt activation and FOXO3a
localization. NHA-E6/E7/hTERT cells were transiently infected with pLXSN-FoxM1B or
pLXSN. Then the cells were immunostained for Akt (green), and their nuclei were stained with
DAPI (blue). The cells were also immunostained for FOXO3a (green), and their nuclei were
stained with DAPI (blue). This is one representative experiment of three. D, Blocking Akt
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activation decreased the colony formation induced by FoxM1. NHA-E6/E7/hTERT cells were
infected with retroviral-pLXSN or pLXSN-FoxM1B for 24 hours and then treated with
LY294002 (25 μM) or wortmannin (0.1 μM) for 2 hours. Left, The expression of FoxM1, p-
Akt, total Akt, FoxO3a, and p-FoxO3a was analyzed by using Western blotting. Right, The
colony-formation ability of the cells was determined by a colony-formation assay. Each bar
represents the mean ± standard deviation of the colony numbers from a representative
experiment in triplicate. *P < 0.01 compared with the no-treatment group.
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Figure 3. FoxM1 down-regulated PTEN expression in NHA cells
A, The expression of FoxM1, PTEN, p-Akt, and Akt in NHA-E6/E7/hTERT/FoxM1B or
parental and NHA-E6/E7/hTERT/pLXSN cells was analyzed by using Western blotting
(left). Paraffin sections from brain injected with pLXSN- and pLXSN-FoxM1B–transduced
NHA-E6/E7/hTERT cells were stained with antibodies against PTEN (right). B, NHA-E6/E7/
hTERT-FoxM1B cells were transfected with FoxM1 siRNA or control siRNA (50 nM) for 48
hours; the expression of FoxM1, PTEN, p-Akt and Akt was analyzed by using Western blotting
(left). Hs683 cells were transfected with pcDNA3.1-FoxM1 and pcDNA3.1 control vector, and
the expression of FoxM1, PTEN, p-Akt, and Akt was analyzed by using Western blotting
(right). C, Real-time PCR analysis of relative mRNA level of FoxM1 and PTEN in pLXSN-
and FoxM1B-transduced NHA-E6/E7/hTERT cells. Each bar represents the mean ± standard
deviation in triplicate. *P < 0.01. D. Cycloheximide chase experiment (left). FoxM1B-
transduced NHA-E6/E7/hTERT cells and pLXSN-transduced NHA-E6/E7/hTERT cells were
treated with CHX (50 mg/ml), and cells were collected at the indicated time for western blotting
analysis of PTEN expression. Relative PTEN protein stability (middle). Intensities of the bands
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in the Western blot were analyzed by using NIH Image software, and the integrated optical
densities of the bands at time zero were set as 100%. Blockade of PTEN decreasing by MG132
(right). pLNCX-PTEN plasmid was co-transfeced with pcDNA3.1-FoxM1 or pcDNA3.1
plasmids into COS-1 cells for 24 hours. MG132 (0–5 μM) was added to the medium as
indicated. The cells were cultured for another 24 hours, and Western blotting was performed.
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Figure 4. FoxM1 down-regulated PTEN expression by regulating NEDD4-1
A, NHA-E6/E7/hTERT-FoxM1B cells were transfected with NEDD4-1-siRNA (50 nM) for
24 hours and then treated with CHX (50 mg/ml) for 6 hours; cells were collected for Western
blotting of NEDD4-1 and PTEN expressions. B. The expression of FoxM1, NEDD4-1, and
PTEN in parental and pLXSN- or FoxM1B-transduced NHA-E6/E7/hTERT cells was
analyzed by using Western blotting (left). Real-time PCR analysis of relative mRNA level of
NEDD4-1 in NHA-E6/E7/hTERT/pLXSN cells and FoxM1B cells (middle). NHA-E6/E7/
hTERT-FoxM1B cells were transfected with FoxM1-siRNA or control siRNA (50 nM) for 48
hours and Western blottings were performed using the antibodies as indicated (right). C,
Upper panel, the schematic structure of NEDD4-1 promoter shows the sequences and positions
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of putative FoxM1-binding sits on the promoter. The grey boxes indicate the putative FoxM1
binding region 1 and 2 in Chip assay. Lower panel, ChIP assays were performed with NHA-
E6/E7/hTERT/pLXSN and FoxM1B cells using an anti-FoxM1 antibody or anti-FoxO3a
antibody (as a control). We subjected 1% of the total cell lysates to PCR before
immunoprecipitation as inputs. D. Hs683 cells were transfected with pcDNA3.1-FoxM1 and
control vector (left). COS1 cells were co-transfected with 2 μg pLNCX-PTEN plasmid with
different dosages of pcDNA3.1-FoxM1 plasmids (right). Cell lysates were collected 48 hours
after the transfections for Western blotting using the antibodies as indicated.
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Figure 5. FoxM1 induced multiple occurrences of cancer-related gene expression
A, The expression of FoxM1, survivin, cyclin D1, and cyclin E in parental, NHA-E6/E7/
hTERT/pLXSN or FoxM1B cells was analyzed by using Western blotting. B, Paraffin sections
from brain injected with pLXSN- or pLXSN-FoxM1B–transduced NHA-E6/E7/hTERT cells
were stained with antibodies against survivin, cyclin D1, and cyclin E (magnification ×200).
C, HFU-251 cells were transfected with FoxM1-siRNA (50 μM), and the expression of FoxM1,
survivin, cyclin D1, and cyclin E was analyzed by using Western blotting.
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Table 1
Effect of FoxM1B on transformation of immortalized normal human astrocytes (NHAs) and tumor growth in the
brain of nude mice
Transformation
Cell types Colony numbersa
NHA-E6/E7/hTERT 0
NHA-E6/E7/hTERT/pLXSN 0
NHA-E6/E7/hTERT/FoxM1B 1512 ± 91
Tumor growth in the brains of nude mice
Cell line
Incidence of tumor
formation b
Median days of survival
(range)
NHA-E6/E7/hTERT 0/5 90 (All >90)
NHA- E6/E7/hTERT/pLXSN 0/5 90 (All >90)
NHA- E6/E7/hTERT/FoxM1B-1 5/5 51 (47–58) *
NHA- E6/E7/hTERT/FoxM1B-2 5/5 54 (52–64) *
NHA- E6/E7/hTERT/FoxM1B-3 4/5 63 (52–>90) *
a
NHA-E6/E7/hTERT cells were infected with retroviral constructs containing the FoxM1 expression unit (pLXSN-FoxM1B) or control pLXSN.
Parental and infected NHA-E6/E7/hTERT cells (1 × 104) were plated in soft agar, and colonies were scored after 3 weeks. Results represent mean ±
SD from three separate experiments.
b
Cells (1 × 106 cells) were implanted intracranially into nude mice. Mice were killed when they were moribund or on day 90. Brains were harvested,
and tumor formation was histologically analyzed.
*
P < 0.001.
Results were shown for one representative experiment of two.
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